Search

Your search keyword '"Abuelazm, Mohamed"' showing total 327 results
Start Over Author "Abuelazm, Mohamed"
327 results on '"Abuelazm, Mohamed"'

1. Efficacy and safety of high-power short-duration ablation for atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials.

Author

Amin, Ahmed, Ghaly, Ramy, Ibrahim, Ahmed, Ali, Mohamed, Almaadawy, Omar, Elzahaby, Amr, Abuelazm, Mohamed, Abdelazeem, Basel, and Munir, Muhammad

Subjects
Ablation, Atrial fibrillation, HPSD, High Power, Pulmonary vein isolation, Atrial Fibrillation, Humans, Catheter Ablation, Randomized Controlled Trials as Topic, Time Factors, Operative Time, Treatment Outcome, Pulmonary Veins
Abstract

BACKGROUND: High-power short-duration (HPSD) ablation has emerged as an alternative to conventional standard-power long-duration (SPLD) ablation. We aim to assess the efficacy and safety of HPSD versus SPLD for atrial fibrillation (AF) ablation. METHODS: A systematic review and meta-analysis of randomized controlled trials (RCTs) retrieved from PubMed, WOS, SCOPUS, EMBASE, and CENTRAL were performed through August 2023. We used RevMan V. 5.4 to pool dichotomous data using risk ratio (RR) and continuous data using mean difference (MD) with a 95% confidence interval (CI). PROSPERO ID: CRD42023471797. RESULTS: We included six RCTs with a total of 694 patients. HPSD was significantly associated with a decreased total procedure time (MD: -22.88 with 95% CI [-36.13, -9.63], P = 0.0007), pulmonary vein isolation (PVI) time (MD: -19.73 with 95% CI [-23.93, -15.53], P

Published
2024

44. Navigating the Proteomic Landscape of Menopause: A Review.

Author

Katamesh, Basant E., Futela, Pragyat, Vincent, Ann, Thilagar, Bright, Whipple, Mary, Hassan, Abdul Rhman, Abuelazm, Mohamed, Nanda, Sanjeev, Anstine, Christopher, and Singla, Abhinav

Subjects
HORMONE therapy, POSTMENOPAUSE, WOMEN'S health, NEUROLOGICAL disorders, DISEASE susceptibility
Abstract

Background and Objectives: Proteomics encompasses the exploration of protein composition, regulation, function, and pathways. Its influence spans diverse clinical fields and holds promise in addressing various women's health conditions, including cancers, osteoporosis, and cardiovascular disorders. However, no comprehensive summary of proteomics and menopausal health exists. Our objective was to summarize proteomic profiles associated with diseases and disorders in peri- and postmenopausal women. Materials and Methods: We conducted a comprehensive search of databases including PubMed, Google Scholar, the Cochrane database, Elsevier, and ScienceDirect until 2022. A total of 253 studies were identified, and 41 studies met the inclusion criteria to identify data of interest. These included the study design, disease, and proteomics/proteins of significance, as described by the authors. Results: The 41 studies covered diverse areas, including bone disorders (10 studies), cardiovascular diseases (5 studies), oncological malignancies (10 studies), and various conditions, such as obesity, nonalcoholic liver disease, the effects of hormone replacement therapy, and neurological diseases (16 studies). The results of our study indicate that proteomic profiles correlate with heart disease in peri- and postmenopausal women, with distinct sex differences. Furthermore, proteomic profiles significantly differ between women with and without osteoporosis. Additionally, patients with breast, ovarian, and endometrial cancer exhibit notable variations in proteomic profiles compared to those without these conditions. Conclusions: Proteomics has the potential to enhance risk assessment and disease monitoring in peri- and postmenopausal women. By analyzing unique protein profiles, clinicians can identify individuals with heightened susceptibility to specific diseases or those already affected by established conditions. This review suggests that there is sufficient preliminary data related to proteomics in peri- and postmenopausal women for early identification of cardiovascular disease, osteoporosis, and cancers, disease monitoring, and tailoring individualized therapies. Rigorous validation studies involving large populations are essential before drawing definitive conclusions regarding the clinical applicability of proteomic findings. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

45. Adjunctive left atrial posterior wall isolation for atrial fibrillation: An updated systematic review and meta‐analysis.

Author

Ibrahim, Ahmed A., Elaraby, Ahmed, Almaadawy, Omar, Abuelazm, Mohamed, Hassan, Abdul Rhman, Bakr, Ali, Husain, Muhammad Ashraf, Elsayed, Hesham, and Abdelazeem, Basel

Subjects
MEDICAL information storage & retrieval systems, LEFT heart atrium, PULMONARY veins, PATIENT safety, TREATMENT effectiveness, META-analysis, DESCRIPTIVE statistics, TREATMENT duration, SYSTEMATIC reviews, MEDLINE, ATRIAL fibrillation, MEDICAL databases, ATRIAL arrhythmias, CATHETER ablation, ONLINE information services, DATA analysis software, CONFIDENCE intervals, DISEASE relapse
Abstract

Objective: Posterior left atrial wall isolation (PWI) plus traditional pulmonary vein isolation (PVI) has been proposed as a promising intervention to decrease atrial fibrillation (AF) recurrence. We aim to investigate the efficacy and safety of adding PWI to the traditional PVI in patients with AF. Methods: A systematic review and meta‐analysis was conducted using synthesizing randomized controlled trials (RCTs) retrieved by systematically searching PubMed, Web of Science, SCOPUS, EMBASE, and Cochrane through June 14, 2023. We used Stata version 17 to pool dichotomous data using risk ratio (RR) and continuous data using mean difference (MD), with a 95% confidence interval (CI) (PROSPERO ID: CRD42023446227). Results: We included 11 RCTs with a total number of 1534 patients. Combined ablation with PWI + PVI was not associated with any significant difference over PVI only regarding the recurrence of clinical AF (RR: 0.86 with 95% CI [0.70–1.06]), all atrial arrhythmia (RR: 0.93 with 95% CI [0.82–1.07]), nonatrial fibrillation arrhythmia (RR: 1.22 with 95% CI [0.97–1.53]), early AF (RR: 0.89 with 95% CI [0.62–1.27]), and antiarrhythmic drugs at discharge (RR: 0.83 with 95% CI [0.67–1.04]). However, it was associated with increased total ablation duration (minutes) (MD: 12.58 with 95% CI [6.80–18.37]) and total procedure duration (minutes) (MD: 16.77 with 95% CI [9.63–23.91]), without any significant difference regarding adverse events (RR: 1.05 with 95% CI [0.63–1.74]). Conclusion: While the pooled data from PWI + PVI using point‐by‐point radiofrequency did not suggest a benefit in the recurrence of various atrial arrhythmias compared to PVI alone, PWI+PVI using direct posterior wall ablation, especially with cryoballoon, demonstrated a significant reduction in recurrence of AF/atrial arrhythmias. Also, PWI + PVI significantly increased the ablation and total procedure durations. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

50. Safety and Efficacy of Camostat Mesylate for Covid-19: a systematic review and Meta-analysis of Randomized controlled trials.

Author

Khan, Ubaid, Mubariz, Muhammad, Khlidj, Yehya, Nasir, Muhammad Moiz, Ramadan, Shrouk, Saeed, Fatima, Muhammad, Aiman, and Abuelazm, Mohamed

Subjects
COVID-19, RANDOMIZED controlled trials, COVID-19 treatment, DIAGNOSTIC use of polymerase chain reaction, PROTEASE inhibitors
Abstract

Background: Camostat mesylate, an oral serine protease inhibitor, is a powerful TMPRSS2 inhibitor and has been reported as a possible antiviral treatment against COVID-19. Therefore, we aim to assess the safety and efficacy of camostat mesylate for COVID-19 treatment. Methods: A systematic review and meta-analysis synthesizing randomized controlled trials from PubMed, Scopus, Embase, Cochrane, Web of Science, clinical trials.gov, and medrxiv until June 2023. The outcomes were pooled using Mean difference (MD) for continuous outcomes and risk ratio (RR) for dichotomous outcomes. The protocol is registered in PROSPERO with ID CRD42023439633. Results: Nine RCTs, including 1,623 patients, were included in this analysis. There was no difference between camostat mesylate and placebo in producing negative PCR test results at 1–7 days (RR: 0.76, 95% CI: [0.54, 1.06] P = 0.1), 8–14 days (RR: 1.02, 95% CI: [0.84, 1.23] P = 0.87), or 15–21 days (RR: 0.99, 95% CI: [0.82, 1.19] P = 0.90); clinical resolution of symptoms at 1–7 days (RR: 0.94 (95% CI: 0.58, 1.53) P = 0.81), 8–14 days (RR: 0.91, 95% CI: [0.74, 1.11] P = 0.33,), or 15–21 days (RR: 0.77, 95% CI: [0.40, 1.51] P = 0.45); and time to symptom improvement (MD:-0.38 weeks (95% CI: [-1.42, 0.66] P = 0.47, I2 = 85%). Conclusion: Camostat mesylate did not improve clinical outcomes in patients with COVID-19, compared to placebo. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results